Section 55
Chapter 54,487

Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex

Lin, S.-Y.G.; Desmond, E.; Bonato, D.; Gross, W.; Siddiqi, S.

Journal of Clinical Microbiology 47(11): 3630-3634


ISSN/ISBN: 1098-660X
PMID: 19741086
DOI: 10.1128/jcm.00803-09
Accession: 054486130

The Bactec MGIT 960 system for testing susceptibility to second-line drugs was evaluated with 117 clinical strains in a multicenter study. The four drugs studied were levofloxacin, amikacin, capreomycin, and ethionamide. The critical concentration established for levofloxacin and amikacin was 1.5 microg/ml, that established for capreomycin was 3.0 microg/ml, and that established for ethionamide was 5.0 microg/ml. The overall level of agreement between the agar proportion method and the MGIT 960 system was 96.4%, and the levels of agreement for the individuals drugs were 99.1% for levofloxacin, 100% for amikacin, 97.4% for capreomycin, and 88.9% for ethionamide. The rate of reproducibility of the drug susceptibility testing results between the participating laboratories was 99.5%.

PDF emailed within 0-6 h: $19.90